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Abstract
Background The influence of new-onset atrial fibrillation
(AF) on the long-term prognosis of nonagenarians who
survive acute myocardial infarction (AMI) has not been
demonstrated.
Objective Our aim was to study the association between
new-onset AF and long-term prognosis of nonagenarians
who survive AMI.
Methods From a total of 96 patients aged ≥89 years admitted
during a 5-year period, 64 (67 %) were discharged alive and
are the focus of this study.
Results Mean age was 91.0±2.0 years, and 39 patients
(61 %) were women. During admission, 9 patients (14 %)
presented new-onset AF, 51 (80 %) did not present AF, and 4
(6 %) had chronic AF. During follow-up (mean 2.3±
2.6 years; 6.6±3.6 years in survivors), 58 patients (91 %) died,
including the 9 patients with new-onset AF. Cumulative sur-
vival at 6, 12, 18, 24, and 30 months was 68.3 %, 57.2 %,
49.2 %, 47.6 %, and 31.8 %, respectively. The only two
independent predictors of mortality in the multivariate analysis
were age (hazard ratio [HR] 1.14; 95 % confidence interval
[CI] 1.01–1.28; p=0.04) and new-onset AF (HR 2.3; 95 % CI
1.1–4.8; p=0.02).
Conclusion New-onset AF is a marker of poor prognosis in
nonagenarians who survive AMI.
Keywords Atrial fibrillation . Prognosis . Nonagenarians .
Myocardial infarction
Introduction
The incidence of acute myocardial infarction (AMI) in very
elderly patients is increasing due to rapid ageing of the
population, which is expected to be more noticeable in the
coming years [1]. Atrial fibrillation (AF) is a common find-
ing in patients who have AMI and becomes more frequent
with age. AMI is associated with a sharp increase in the
occurrence of AF. The incidence of AF among AMI patients
ranges between 7 % and 22 % [2, 3] and has increased in
recent years [4]. Although the influence of AF on AMI
remains controversial in younger patients, the bulk of evi-
dence suggests that AF has adverse prognostic implications
after AMI [3, 5, 6]. In fact, a recent meta-analysis concluded
that AF was associated with an increased risk of mortality in
AMI patients with a mean age of 65 years [2]. The studies
mentioned above demonstrated that new-onset AF at the
time of AMI is associated with a higher risk of mortality
than pre-existing AF, for which there is little or no risk of
mortality [2, 5, 6].
Previous data on nonagenarians with AMI are scarce and
are based mainly on studies comprising 100 or fewer patients
with ST-segment elevation AMI (STEMI) [7–10]. In addition,
these studies do not include data on long-term prognosis
[7–9], are not focused on STEMI [10], or only include patients
who have undergone primary percutaneous coronary interven-
tion [8, 9]. In patients who survive AMI, mortality increases
exponentially with age; in fact, age is the strongest predictor of
short-term [11], medium-term [12], and long-term [13] mor-
tality after discharge. As mortality is expected to be high
during follow-up in nonagenarians who survive STEMI, the
prognostic influence of new-onset AF should be easier to
detect in these patients. We hypothesise that new-onset AF
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could be associated with higher all-cause mortality in non-
agenarians who survive STEMI.
Methods
The Myocardial Infarction Management: Observation and
Registry in Elderly patients aged 89 years or older (MIMORE
89) registry has been described previously [14, 15] and com-
prises 96 patients aged ≥89 years with STEMI or complete left
bundle branch block AMI admitted to Hospital General
Universitario ‘Gregorio Marañón’ (Madrid, Spain) from
February 1998 to February 2004. A total of 64 patients
(67 %) were discharged alive and are the focus of this study,
with follow-up until December 2011.
Categorical variables were compared using the chi-square
test (or Fisher’s exact test, when indicated); continuous var-
iables were compared using the t test. We performed a
backward stepwise Cox regression analysis with all relevant
clinical variables to study independent predictors of long-
term mortality. This Cox regression was repeated excluding
patients with chronic AF. Results are expressed as the hazard
ratio (HR) and 95 % confidence interval (CI). All analyses
were performed with SPSS 11.0 (SPSS, Inc., Chicago,
Illinois, USA).
The study complies with the Declaration of Helsinki and
was approved by the Ethics Committee of Hospital General
Universitario Gregorio Marañón, Madrid, Spain.
Results
Overall population
The independent predictors of in-hospital mortality have
been published elsewhere [14] and did not include new-
onset AF. At admission, 14 patients (14.6 %) presented
new-onset AF, 73 (76.0 %) did not present AF, and 9
(9.4 %) had chronic AF. In-hospital mortality was similar
in patients with and without new-onset AF (35.7 % vs.
32.9 %, respectively). A total of 64 patients (67 %) were
discharged alive and are the focus of this study.
Patients discharged alive
Mean age was 91.0±2.0 years, and 39 patients (61 %) were
women. During the index AMI admission, 9 patients (14 %)
presented new-onset AF, 51 (80 %) did not present AF, and 4
(6 %) had chronic AF. The CHA2DS2 VASc score [16] was
similar in patients with new-onset AF and in those with
chronic AF (5.0±1.4 and 5.3±1.5, respectively), and only
3 patients (4.7 %) received warfarin at discharge. The clinical
characteristics and discharge treatment (Table 1) of patients
with or without new-onset AF were similar. During long-
term follow-up (mean 2.3±2.6 years; 6.6±3.6 years in sur-
vivors), 58 patients died (91 %), including the 9 patients with
new-onset AF (Fig. 1). We were able to identify the cause of
death in 16 patients (29 %); the most frequent causes were
heart failure (5 patients), stroke (3 patients), and a new AMI
(2 patients). A total of 6 patients died from non-cardiac
causes (2 hip fractures, 2 respiratory infections, 1 pulmonary
embolism, and 1 head injury). Cumulative survival at 6, 12,
18, 24, and 30 months was 68.3 %, 57.2 %, 49.2 %, 47.6 %,
and 31.8 %, respectively. The only two independent predic-
tors of mortality in the multivariate analysis were age (HR
1.16; 95 % CI 1.02–1.31; p=0.03) and new-onset AF (HR
2.3; 95 % CI 1.1–4.7; p=0.01). The results excluding 4
patients with chronic AF were similar, as follows: age (HR
1.14; 95 % CI 1.01–1.28; p=0.04) and new-onset AF (HR
2.3; 95 % CI 1.1–4.8; p=0.02).
Discussion
Long-term follow-up of the MIMORE 89 registry shows that
new-onset AF in nonagenarians who survive AMI has seri-
ous adverse implications for long-term mortality. In this
high-risk population, new AF was a strong predictor of all-
cause mortality.
As expected, the incidence of AF in our population (15 %
new-onset, 9 % previous) was higher than previously de-
scribed in younger populations [2–4] and similar to the
incidence found in a population of nonagenarians with
AMI [10]. Data on nonagenarians with STEMI are scarce
and do not cover long-term prognosis [7–10]; therefore,
there is no previous evidence for the influence of new-
onset AF on long-term prognosis of very elderly patients
who survive AMI. All of the 9 patients with new-onset AF
who were discharged died during follow-up. Interestingly, 6
of these patients died in the first 4 months after discharge,
suggesting that new-onset AF affects the short-term progno-
sis of nonagenarians who survive AMI. Moreover, the clin-
ical characteristics of patients with new-onset AF were sim-
ilar to those of patients who did not present this condition
during admission; this could imply that new-onset AF is
more than a marker of advanced disease.
There are several potential explanations for the observed
association between increased all-cause mortality and AF
in elderly patients with AMI. The morphofunctional char-
acteristics of the heart in the very elderly [17], including
increased left ventricular thickness, suggest a high suscep-
tibility to new-onset AF that could lead to adverse outcome
through haemodynamic effects such as loss of atrial con-
traction, rapid ventricular rates, loss of atrioventricular
synchrony, and irregular RR interval, all of which lead to
a decrease in cardiac output [18]. AF can also predispose to
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ventricular arrhythmia after AMI [19]. Finally, new-onset
AF in patients with AMI carries a substantial future risk for
stroke [4, 6, 20], which is particularly high in nonagenar-
ians. Interestingly, of the 16 patients with a known cause of
death during follow-up, 3 died from stroke. Despite a high
CHA2DS2 VASc score, oral anticoagulants were very rare-
ly prescribed to these patients, and even clopidogrel was
rarely used.
Table 1 Clinical characteristics
and treatment of 64 patients aged
≥89 years discharged after acute
myocardial infarction with and
without new-onset atrial fibrilla-
tion (AF)
AMI acute myocardial infarction
COPD chronic obstructive pulmo-
nary disease






a Echocardiography in 60 patients
b Coronary angiography in 22
patients
Variable, n (%) No new-onset AF (n=55) New-onset AF (n=9) P
Age ≥89 years 24 (43.6) 5 (55.6) 0.54
Women 32 (58.2) 7 (77.8) 0.25
Diabetes 14 (25.5) 2 (22.2) 0.84
Hypertension 38 (69.1) 7 (77.8) 0.60
COPD 9 (16.4) 2 (22.2) 0.67
Renal disease 6 (10.9) 1 (11.1) 0.99
Stroke 9 (16.4) 1 (11.1) 0.69
Anterior AMI 16 (29.1) 2 (22.2) 0.92
LVEF ≤0.3a 17 (32.7) 5 (55.6) 0.68
Primary PTCA 11 (20.0) 2 (22.2) 0.89
No reperfusion therapy 38 (69.0) 7 (77.8) 0.60
Multivessel diseaseb 11 (68.8) 2 (66.7) 0.95
PTCA 17 (30.9) 3 (33.3) 0.90
Aspirin 50 (90.9) 8 (88.9) 0.87
Warfarin 2 (3.6) 1 (11.1) 0.31
Beta-blockers 28 (51) 6 (66.7) 0.40
ACE inhibitors 44 (80.0) 9 (100) 0.15
Clopidogrel 18 (32.7) 2 (22.2) 0.54
Statins 15 (27.3) 4 (44.4) 0.56
Number at risk
New AF 9 2 00 0 1
No new AF 48122855 0
0 2 4 6 8 10
No new AF
New AF
Fig. 1 Kaplan-Meier curves for
patients aged ≥89 years
discharged after acute
myocardial infarction with and
without new-onset atrial
fibrillation (new AF)
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Age is the strongest predictor of mortality after discharge
[11–13]; therefore, the high mortality we found (51 % at
18 months) was expected. Interestingly, even in this very
elderly population, age was still an important predictor of
prognosis, suggesting that the previously described deleteri-
ous effect of age on the prognosis of elderly patients with
AMI persists in nonagenarians. Most patients had multives-
sel coronary artery disease, and severe left ventricular dys-
function was common; both factors probably contributed to
the poor prognosis of our cohort. In addition, most non-
agenarians in our study were women, a finding that is con-
sistent with the generally longer life expectancy of women,
although the association between female sex and prognosis
is probably dependent on comorbid conditions and age.
Comorbid conditions were very common in our population
and mainly included diabetes, chronic obstructive pulmo-
nary disease, renal disease, and stroke. The importance of
these conditions is reflected in the high frequency of non-
cardiac deaths in our registry.
Limitations and strengths
As this is a relatively small single-centre study, our findings
may not be generalisable to other populations, and confir-
mation in larger and more diverse series is desirable. In
addition, we were unable to assess other relevant outcomes,
such as re-hospitalisation and quality of life. Caution must be
exercised when evaluating all-cause mortality and differen-
ces between the two groups, given the relatively small num-
ber of patients studied. However, the long follow-up and
high mortality overcome this limitation. Although our data
show a strong association between AF and poor prognosis, it
is still unclear whether AF per se is a complication of AMI or
merely demarcates the severity of AMI.
One of the strengths of our study is that the cohort com-
prised a relatively contemporary and consecutive series of
well-characterised patients ≥89 years of age with docu-
mented STEMI. We also had complete follow-up informa-
tion with respect to vital status over a mean duration of
5 years after hospital admission. The high mortality rate
afforded excellent statistical power, which made it possible
to identify independent predictors of decreased survival.
Conclusion
New-onset AF is common in nonagenarians who survive
AMI and is a strong marker of poor prognosis.
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